SCHOLAR ROCK HOLDING CORPORATION Shareholders' Equity
SCHOLAR ROCK HOLDING CORPORATION (SRRK) had Shareholders' Equity of $253.78 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:StockholdersEquity · last filed 2026-08-06
- 2026-06-30: Stockholders' Equity Attributable to Parent $253.78M.
- 2026-03-31: Stockholders' Equity Attributable to Parent $276.01M.
- 2025-12-31: Stockholders' Equity Attributable to Parent $245.49M.
- 2025-09-30: Stockholders' Equity Attributable to Parent $245.00M.
| Period end | Stockholders' Equity Attributable to Parent |
|---|---|
| 2026-06-30 | $253.78M 10-Q · filed 2026-08-06 |
| 2026-03-31 | $276.01M 10-Q · filed 2026-08-06 |
| 2025-12-31 | $245.49M 10-Q · filed 2026-08-06 |
| 2025-09-30 | $245.00M 10-Q · filed 2025-11-14 |
| 2025-06-30 | $233.29M 10-Q · filed 2026-08-06 |
| 2025-03-31 | $312.33M 10-Q · filed 2026-08-06 |
| 2024-12-31 | $368.63M 10-Q · filed 2026-08-06 |
| 2024-09-30 | $79.20M 10-Q · filed 2025-11-14 |
| 2024-06-30 | $133.62M 10-Q · filed 2025-11-14 |
| 2024-03-31 | $182.77M 10-Q · filed 2025-11-14 |
| 2023-12-31 | $225.22M 10-K · filed 2026-03-03 |
| 2023-09-30 | $167.66M 10-Q · filed 2024-11-12 |
| 2023-06-30 | $202.50M 10-Q · filed 2024-11-12 |
| 2023-03-31 | $228.65M 10-Q · filed 2024-11-12 |
| 2022-12-31 | $260.24M 10-K · filed 2025-02-27 |
| 2022-09-30 | $293.26M 10-Q · filed 2023-11-07 |
| 2022-06-30 | $329.51M 10-Q · filed 2023-11-07 |
| 2022-03-31 | $171.32M 10-Q · filed 2023-11-07 |
| 2021-12-31 | $172.07M 10-K · filed 2024-03-19 |
| 2021-09-30 | $187.26M 10-Q · filed 2022-11-14 |
| 2021-06-30 | $216.66M 10-Q · filed 2022-11-14 |
| 2021-03-31 | $240.54M 10-Q · filed 2022-11-14 |
| 2020-12-31 | $260.77M 10-K · filed 2023-03-07 |
| 2020-09-30 | $62.98M 10-Q · filed 2021-11-09 |
| 2020-06-30 | $82.17M 10-Q · filed 2021-11-09 |
| 2020-03-31 | $98.65M 10-Q · filed 2021-11-09 |
| 2019-12-31 | $112.90M 10-K · filed 2022-03-07 |
| 2019-09-30 | $121.79M 10-Q · filed 2020-11-09 |
| 2019-06-30 | $128.96M 10-Q · filed 2020-11-09 |
| 2019-03-31 | $97.52M 10-Q · filed 2020-11-09 |
| 2018-12-31 | $106.62M 10-K · filed 2021-03-09 |
| 2018-09-30 | $102.34M 10-Q · filed 2019-11-12 |
| 2018-06-30 | $111.61M 10-Q · filed 2019-11-12 |
| 2018-03-31 | -$61.93M 10-Q · filed 2019-11-12 |
| 2017-12-31 | -$53.52M 10-K · filed 2020-03-12 |
| 2016-12-31 | -$30.03M 10-K · filed 2019-03-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 | |
| IOVANCE BIOTHERAPEUTICS, INC. (IOVA) | United States | $4.897B | -6.51 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |